Abstract
Since the COVID-19 emergence in December 2019, significant efforts are being made in the hunt for appropriate medical interventions. This forces scientists to produce or discover traditional curative medications, preventive vaccinations, or passive immunological techniques as quickly as possible. Therapeutic monoclonal antibodies (mAbs) have drawn a lot of interest throughout this context. COVID-19 approved Emergency Use Authorization (EUA) medications for the outpatient treatment of mild to moderate symptoms for many monoclonal antibodies (mAbs) aimed against the Receptor binding domain of the S protein of the coronavirus 2 (SARS-CoV-2). We investigated the feasibility of monoclonal antibodies for the diagnosis and treatment of COVID-19 infection in this review. Human monoclonal antibodies targeted SARS-CoV-2 viral protein domains, especially the spike protein area, and hyper-immune plasma from recovered COVID-19 patients are also included in this review. In summary, monoclonal antibodies are the promising remedies that could be used to regulate the SARS-CoV-2 (COVID-19 infection causal agent) through immunotherapy, vaccine development, and viral screening.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
